/ABSI
ABSI Stock - Absci Corporation
Healthcare|BiotechnologyNASDAQ
$3.31-2.65%
$0.09 (-2.65%) • Jan 13
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.54
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.35
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+86.1%upside
Target: $6.16
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABSI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.28 – $3.34
TARGET (TP)$6.16
STOP LOSS$3.05
RISK/REWARD1:11.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.13
52W High$6.33
52W Low$2.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.53M | $5.72M | $5.75M | $4.78M | $4.78M |
| Gross Profit | $-57,925,000 | $-41,849,000 | $-53,161,000 | $-39,804,000 | $-6,668,000 |
| Gross Margin | -1277.6% | -731.9% | -925.0% | -832.4% | -139.5% |
| Operating Income | $-108,888,000 | $-115,515,000 | $-106,750,000 | $-75,238,000 | $-13,301,000 |
| Net Income | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 | $-14,353,000 |
| Net Margin | -2274.1% | -1933.6% | -1825.4% | -2111.3% | -300.3% |
| EPS | $-0.94 | $-1.20 | $-1.15 | $-1.11 | $-0.54 |
Company Overview
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ABSIBeat Rate
11%
Last 18 quarters
Avg Surprise
-20.9%
EPS vs Estimate
Beats / Misses
2/15
1 met exactly
Latest EPS
$-0.20
Q4 2025
EPS Surprise History
Q1 24
-8.7%
$-0.25vs$-0.23
Q2 24
-15.8%
$-0.22vs$-0.19
Q3 24
-15.8%
$-0.22vs$-0.19
Q4 24
-26.3%
$-0.24vs$-0.19
Q1 25
-13.6%
$-0.25vs$-0.22
Q2 25
+8.7%
$-0.21vs$-0.23
Q3 25
-26.3%
$-0.24vs$-0.19
Q4 25
-5.3%
$-0.20vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.27 | $-0.30 | -11.1% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.32 | $-0.32 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q1 2022 | Mar 22, 2022 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.21 | $-0.28 | -33.3% | ✗ MISS |
Q3 2021 | Sep 7, 2021 | $-0.85 | $-2.39 | -181.2% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ABSI
What is ABSI's current stock price?
Absci Corporation (ABSI) is currently trading at $3.31 per share. The stock has moved -2.65% today.
What is the analyst price target for ABSI?
The average analyst price target for ABSI is $6.16, based on 1 analyst.
What sector is Absci Corporation in?
Absci Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABSI's market cap?
Absci Corporation has a market capitalization of $0.50 billion, making it a small-cap company.
Does ABSI pay dividends?
No, Absci Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRVS
Corvus Pharmaceuticals, Inc.
$6.50
Mkt Cap: $0.5B
ERAS
Erasca, Inc.
$7.50
Mkt Cap: $2.1B
GOSS
Gossamer Bio, Inc.
$2.66
Mkt Cap: $0.6B
MGTX
MeiraGTx Holdings plc
$7.38
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$17.10
Mkt Cap: $1.1B
OLMA
Olema Pharmaceuticals, Inc.
$27.89
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$8.98
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$15.05
Mkt Cap: $0.8B
VSTM
Verastem, Inc.
$7.20
Mkt Cap: $0.4B
VTYX
Ventyx Biosciences, Inc.
$13.86
Mkt Cap: $1.0B
Explore stocks similar to ABSI for comparison